Quest Diagnostics Inc Stock Price, News & Analysis

A Quest Diagnostics study reveals that cancer diagnoses, particularly breast and prostate cancers, remain significantly below pre-pandemic levels, with a nearly 30% decline observed in early 2020. The analysis of over 1.1 million test results indicates that undiagnosed cancer cases have risen since the pandemic, leading to potential adverse outcomes and higher healthcare costs. Key findings include an 11% decline in diagnoses from April 2021 to March 2022, with breast and prostate cancer diagnoses still down by 11% and 17%, respectively. The study underscores the importance of routine screenings to mitigate rising health risks.

Quest Diagnostics (NYSE: DGX) has announced a definitive agreement to acquire select assets of Summa Health's LabCare Plus outreach laboratory services in an all-cash transaction. This acquisition aims to broaden access to innovative, quality laboratory services in Ohio, enhancing care affordability. Post-transaction, Quest will provide testing through its labs in Twinsburg and Pittsburgh, while Summa will maintain its hospital labs. The transaction, expected to close in Q4 2022, follows a competitive bid process, though financial details remain undisclosed.

Quest Diagnostics (NYSE: DGX) will report its third quarter 2022 financial results on October 20, 2022, before the market opens. The company will hold a conference call at 8:30 a.m. ET to discuss these results. Investors can access the call by dialing 888-455-0391 (U.S./Canada) or 773-756-0467 (international) with the passcode 7895081. Earnings release and live webcast will be available on the company's investor website. A replay of the call will be accessible until November 3, 2022.

Quest Diagnostics (NYSE: DGX) partners with Lee Health to enhance diagnostic services, aiding patient care amid post-COVID challenges. This collaboration will leverage Quest's supply chain expertise to streamline lab operations across five Lee Health hospitals and selected outpatient centers. The partnership is expected to improve efficiency and quality of care, with Quest providing procurement support and continuing reference testing services. This strategic alliance reflects Quest's commitment to advancing healthcare outcomes for patients in Southwest Florida.

Achievers and Quest Diagnostics have jointly won a Gold award from Brandon Hall Group for the Best Advance in Employee Recognition Program in the Talent Management category. This accolade recognizes their effective workplace strategy in enhancing employee performance through recognition. The collaboration emphasizes Quest's commitment to fostering a culture of appreciation, especially after relaunching RecognitionQuest in 2020. The award ceremony is set for the HCM Excellence Conference from Jan. 31-Feb. 2, 2023, in West Palm Beach, Florida.

Takeda has launched the CDPATH™ program, a personalized prognostic tool designed for Crohn's disease patients in the U.S. This tool predicts the risk of developing serious complications within three years using blood tests, and it's offered at no cost to eligible adult patients. The program aims to facilitate shared decision-making between patients and healthcare providers by integrating patient-specific markers with clinical assessments. CDPATH is available through over 2,500 locations nationwide, enhancing patient-centered care for over three million people affected by inflammatory bowel disease.

Quest Diagnostics (NYSE: DGX) is set to present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 4:40 p.m. Eastern Time. CEO-elect Jim Davis and CFO Sam Samad will outline the company's vision and capital strategies. The presentation will be accessible via a live webcast on their investor relations page and archived for later viewing until October 13, 2022. Quest Diagnostics is a premier provider of diagnostic services, serving a significant portion of healthcare professionals and patients in the U.S.

Quest Diagnostics (NYSE: DGX) has received emergency use authorization (EUA) from the FDA for its lab-developed test specifically designed to detect Monkeypox virus DNA. This marks the first EUA granted for a commercially available Monkeypox test in the U.S. The Quest Monkeypox PCR test detects DNA from Monkeypox and non-variola Orthopoxvirus in lesion swabs, providing a crucial tool for diagnosis amid the ongoing public health emergency. The test's dual-target capability minimizes false negatives, enhancing reliability. It is now available nationwide, complementing public health laboratory efforts.

uMETHOD partners with Getlabs to provide at-home lab services for Arizona patients, enhancing accessibility for those with cognitive decline, including mild dementia and Alzheimer's disease. In just one month, mobile service usage quadrupled in the Greater Phoenix area. This partnership aims to improve treatment compliance and patient independence by connecting diagnostics with actionable treatment plans through uMETHOD's RestoreU program. With over 150,000 Arizonans affected by cognitive decline, this initiative addresses a critical healthcare need while collaborating with Sonora Quest Laboratories for efficient sample testing.